Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05437965 (National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
Typeobservational_patient_registrySponsorChina National Center for Cardiovascular DiseasesRan2020 to 2035Enrolled1,000ConditionsCoronary Artery Disease, Arteritis, In-Stent Stenosis (Restenosis) of Coronary Artery StentArmsTreatment made by experienced clinicians
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Lei Jia *Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China.
Ke Wang *Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China.ORCID http://orcid.org/0000-0002-1039-7385
Zhangyu Lin *Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China.ORCID http://orcid.org/0000-0001-9240-9724
Dong YinDepartment of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China.
Wanjie RenDepartment of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China.
Zongyao Zhang *Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China.
Wei Fang *Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China. nuclearfw@126.com.
Lei Wang *Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China. leiwangfw@126.com.ORCID http://orcid.org/0000-0003-0273-6129
Kefei Dou *Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, China. drdoukefei@126.com.ORCID http://orcid.org/0000-0002-8372-6338
Funding
Beijing Nova Program 20230484328National High Level Hospital Clinical Research Funding 2024-GSP-TJ-2National Natural Science Foundation of China 82370345
6 · The paper itself
Abstract
purposeTo investigate the potential of
methodsThis prospective study enrolled participants with ISR selected from a cohort registry between December 2024 to August 2025, which was categorized into rapid recurrent ISR (R-ISR) and ordinary ISR (O-ISR) based on recurrence time interval. For vessel-level analysis, coronary arteries without intervention served as control. All participants underwent both
resultsThirty-one participants and 84 vessels were included. ISR vessels (n = 39) demonstrated higher uptake in
conclusion
trial registrationNCT05437965. Registered 24 June 2022.
Indexed as
Coronary RestenosisFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyStentsAgedFemaleFibroblast Activation Protein AlphaHumansMaleMiddle AgedPhenotypeProspective StudiesQuinolinesRisk Assessment68Ga-FAPIFibroblast Activation Protein AlphaFluorodeoxyglucose F18Quinolines18F-FAPI18F-FDGIn-stent restenosisPET/CT
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Molecular phenotyping with · full record | Socratic